Cargando…
Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000641/ https://www.ncbi.nlm.nih.gov/pubmed/32013312 http://dx.doi.org/10.5217/ir.2019.09155 |
_version_ | 1783494076378644480 |
---|---|
author | Park, Soo-Kyung Choi, Chang Hwan Chun, Jaeyoung Lee, Heeyoung Kim, Eun Sun Park, Jae Jun Park, Chan Hyuk Lee, Bo-In Jung, Yunho Park, Dong-Il Kim, Do Young Park, Hana Jeen, Yoon Tae |
author_facet | Park, Soo-Kyung Choi, Chang Hwan Chun, Jaeyoung Lee, Heeyoung Kim, Eun Sun Park, Jae Jun Park, Chan Hyuk Lee, Bo-In Jung, Yunho Park, Dong-Il Kim, Do Young Park, Hana Jeen, Yoon Tae |
author_sort | Park, Soo-Kyung |
collection | PubMed |
description | The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host’s immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD. |
format | Online Article Text |
id | pubmed-7000641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Korean Association for the Study of Intestinal Diseases |
record_format | MEDLINE/PubMed |
spelling | pubmed-70006412020-02-12 Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases Park, Soo-Kyung Choi, Chang Hwan Chun, Jaeyoung Lee, Heeyoung Kim, Eun Sun Park, Jae Jun Park, Chan Hyuk Lee, Bo-In Jung, Yunho Park, Dong-Il Kim, Do Young Park, Hana Jeen, Yoon Tae Intest Res Review The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host’s immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD. Korean Association for the Study of Intestinal Diseases 2020-01 2020-01-30 /pmc/articles/PMC7000641/ /pubmed/32013312 http://dx.doi.org/10.5217/ir.2019.09155 Text en © Copyright 2020. Korean Association for the Study of Intestinal Diseases. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Park, Soo-Kyung Choi, Chang Hwan Chun, Jaeyoung Lee, Heeyoung Kim, Eun Sun Park, Jae Jun Park, Chan Hyuk Lee, Bo-In Jung, Yunho Park, Dong-Il Kim, Do Young Park, Hana Jeen, Yoon Tae Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases |
title | Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases |
title_full | Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases |
title_fullStr | Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases |
title_full_unstemmed | Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases |
title_short | Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases |
title_sort | prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the korean association for the study of intestinal diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000641/ https://www.ncbi.nlm.nih.gov/pubmed/32013312 http://dx.doi.org/10.5217/ir.2019.09155 |
work_keys_str_mv | AT parksookyung preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT choichanghwan preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT chunjaeyoung preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT leeheeyoung preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT kimeunsun preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT parkjaejun preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT parkchanhyuk preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT leeboin preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT jungyunho preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT parkdongil preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT kimdoyoung preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT parkhana preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT jeenyoontae preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases AT preventionandmanagementofviralhepatitisininflammatoryboweldiseaseaclinicalpracticeguidelinebythekoreanassociationforthestudyofintestinaldiseases |